IL2 and non-small cell lung carcinoma: For example, combinatorial treatment of low doses of interleukin-2 (IL-2) and TNF-α in NSCLC patients has resulted in enhanced tumor regression [12], making these pro-inflammatory cytokines an attractive choice of therapeutic agent to be used in immunotherapy to treat cancer.